Universal Cells
Kim Clary is currently the Executive Director of Clinical Gene Editing & Strategy at Universal Cells, having previously held various roles at the company including Director of Operational Excellence and Senior Project Manager. Prior to that, Kim worked at Infectious Disease Research Institute and Targeted Genetics Corporation/Ampliphi BioSciences in positions ranging from Vice President of Alliance Management to Staff Scientist in Immunology. Kim holds a PhD in Microbiology and Immunology from Southern Illinois University and a Bachelor of Science in Microbiology and Immunology from the University of Illinois Urbana-Champaign.
This person is not in any teams
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.